Physician profile
Matthew Mukherjee
NPI 1548439458
$10,832.19
in general payments reported to CMS, 2019-2025
49 companies · $2,023 in 2025
The $2,023 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,455 · 2020: $445 · 2021: $1,304 · 2022: $2,462 · 2023: $2,004 · 2024: $1,139 · 2025: $2,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,030 · Education: $136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,030.34 |
| Education | $136.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,026.73 | 2019-2025 | |
| Janssen Biotech, INC. | $1,402.52 | 2019-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $770.03 | 2019-2023 | Xifaxan, Trulance |
| Boston Scientific Corporation | $726.96 | 2019-2024 | |
| Celgene Corporation | $444.16 | 2021-2023 | Zeposia |
| Pfizer INC. | $381.17 | 2019-2025 | |
| Ardelyx, INC. | $334.16 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $323.45 | 2019-2023 | Dificid |
| Ferring Pharmaceuticals INC. | $310.03 | 2019-2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $285.95 | 2022-2025 | Dupixent |
| Madrigal Pharmaceuticals | $278.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $262.25 | 2019-2024 | Entyvio |
| Gilead Sciences, INC. | $239.24 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $151.03 | 2019-2023 | Linzess |
| Organon LLC | $126.41 | 2021-2023 | Hadlima |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $121.25 | 2022 | |
| Celltrion USA INC. | $116.66 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $116.63 | 2019-2023 | Ocaliva |
| Cook Medical LLC | $111.54 | 2019 | |
| Lilly USA, LLC | $96.77 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $89.72 | 2021-2025 | Sucraid, Sucraid |
| Daiichi Sankyo INC. | $81.12 | 2019-2022 | |
| Evoke Pharma, INC. | $77.08 | 2022-2023 | Gimoti |
| Genzyme Corporation | $76.98 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $76.19 | 2023-2025 | Zenpep |
| Mallinckrodt Hospital Products INC. | $72.75 | 2022-2024 | Terlivaz |
| Capsovision, INC. | $62.10 | 2025 | Capsocam Plus |
| Amgen INC. | $54.00 | 2021 | |
| Braintree Laboratories, INC. | $53.80 | 2019-2022 | |
| Fresenius Kabi USA, LLC | $50.94 | 2023 | |
| Shionogi INC | $46.32 | 2019 | |
| Medtronic, INC. | $42.88 | 2021-2024 | Gi Genius |
| Ambu INC. | $39.02 | 2021 | |
| Exact Sciences Corporation | $38.73 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ucb, INC. | $38.34 | 2019 | |
| Allergan, INC. | $37.37 | 2019-2020 | |
| Pacira Pharmaceuticals Incorporated | $37.21 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.59 | 2024 | Cyltezo |
| Novo Nordisk INC | $28.44 | 2025 | Wegovy |
| Redhill Biopharma INC. | $27.90 | 2020 | |
| Sandoz INC. | $25.23 | 2023 | Hyrimoz |
| Alfasigma USA, INC. | $22.01 | 2020 | |
| Phathom Pharmaceuticals, INC. | $21.85 | 2024 | Voquezna |
| Shield Therapeutics INC | $16.17 | 2023 | Accrufer |
| Vivus LLC | $14.45 | 2019 | |
| Shire North American Group INC | $14.42 | 2019 | |
| Lucid Diagnostics INC. | $13.97 | 2022 | |
| W. L. Gore & Associates, INC. | $13.28 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Mukherjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.